- category:Pipeline
Pipeline
Enrollment opens for Clearside Biomedical's ODYSSEY phase 2b trial for wet AMD
CLS-AX is being assessed for suprachoroidal delivery using the company’s proprietary CSC Microinjector.
Pipeline
Target enrollment achieved in trial for RP associated with Usher syndrome
The phase 1/2 study is assessing NPI-001, developed to block oxidative stress associated with RP and other blinding eye diseases.
Pipeline
Positive 12-month data reported in Coave's ongoing RP phase 1/2 trial
Gene therapy candidate targets treatment for a rare form of retinitis pigmentosa: PDE6B RP.
Pipeline
4DMT reports positive interim data from phase 1/2 wet AMD trial
4D Molecular Therapeutics’ intravitreal study on novel genetic medicine indicates well-tolerance for all doses.
Pipeline
Annexon releases topline data for phase 2 GA study
ARCHER trial is assessing ANX007 as the first complement therapy for preserving visual acuity.
Pipeline
Alimera completes patient enrollment for DME study on ILUVIEN
NEW DAY study is evaluating the intravitreal implant as a baseline therapy compared to aflibercept.
Pipeline
Tanfanercept fails DED phase 3 trial primary endpoints
HanAll Biopharma reports highly statistically significant improvement in secondary measures of VELOS-3 study.
Pipeline
Positive topline data reported in phase 3 DME trial of OCS-01
Oculis’s stage 1 of the DIAMOND study supports potential for OCS-01 to become the first topical eye drop and noninvasive DME treatment.
Pipeline
RegenxBio to globally expand pivotal trials for wet AMD gene therapy
Company shares updates on development and commercialization plans for ABBV-RGX-314.
Pipeline
Enrollment concludes for Invirsa's first-in-human DED study
Lead compound INV-102 is formulated to promote ocular DNA repair.
Pipeline
First patient dosed in phase 2, China-based TED trial
The RESTORE trial is assessing the proptosis responder rate following dosage of IBI311, an IGF-1R monoclonal antibody.
Pipeline
Formosa and AimMax submit joint NDA for ocular pain and inflammation
Novel ophthalmic APP13007 is designed to provide eye comfort and enhanced drug penetration into ocular tissues.
Pipeline
Phase 2 data of TTHX1114 shows promise for improving post-DSO visual recovery rate
Trefoil Therapeutics’ first investigational FGF-1 improved BCVA and CCT.
Pipeline
FDA accepts sBLA for Vabysmo to treat RVO
If approved, Vabysmo would become the first bispecific antibody available for blinding retinal conditions.
Pipeline
Atia Vision presents first-in-human clinical data from novel IOL
Early results show potential for both cataract and presbyopia correction.
Pipeline
Visus releases topline data from phase 3 trial of Brimochol PF
BRIO-I trial successfully meets prespecified FDA primary endpoints.
Pipeline
Endogena concludes enrollment ahead of schedule for RP trial
Phase 1/2a dose expansion trial is assessing the safety and tolerability of EA-2353.
Pipeline
Nanoscope releases key efficacy data from phase 2b trial for RP
Clinically significant vision improvement observed among patients treated with the optogenetic therapy MCO-010.
Pipeline
Favorable preliminary data reported for KIO-301 in RP treatment
Kiora Pharmaceuticals' first-in-human ABACUS study suggests promising vision function restoration.
Pipeline